Table 1

Patient's characteristics at baseline

NMinMaxMeanSD95% CI of meanMedianIQR
Age (years)26238555.2314.48(49.38 to 61.08)5321
Body mass index2621.638.326.503.67(25.02 to 27.98)26.254.2
Duration of PsA (years)261266.546.72(3.82 to 9.25)44
Duration of remission (months)26612023.9223.68(14.36 to 33.49)16.5025
Duration of DMARD (months)2176034.3813.89(28.06 to 40.70)3622
Duration of TNFi (months)12714541.1735.97(18.31 to 64.02)3530
TJC 6826020.190.56(−0.04 to 0.42)00
SJC 66260000(0 to 0)00
VAS patient global (cm)24030.830.93(0.44 to 1.22)0.551.50
VAS patient pain (cm)22020.670.77(0.33 to 1.01)0.351
VAS physician global (cm)25010.100.22(0.01 to 0.19)00
CRP (mg/L) to 2.59)1.051.40
ESR (mm/h)221368.647.71(5.22 to 12.06)88
DAS-28 CRP250.962.341.370.36(1.22 to 1.52)1.280.60
DAPSA220.036.031.851.64(1.13 to 2.58)1.952.64
PASDAS230.203.411.120.78(0.78 to 1.46)1.081.27
HAQ-DI2602.120.160.44(−0.02 to 0.33)00.12
SF-36 (physical component scale)2420.9162.7550.69(46.80 to 54.39)53.457.29
SF-36 (mental component scale)2433.4662.1652.96.37(50.20 to 55.59)54.268.54
FACIT-F222752456.73(42.02 to 47.98)478
MASES260000(0 to 0)00
LDI260000(0 to 0)00
BASDAI2303.61.551.16(1.04 to 2.05)1.602.10
PASI2602.40.210.56(−0.01 to 0.44)00
NAPSI260264.306.90(1.52 to 7.09)25
  • SJC, MASES, LDI: no descriptive statistics were calculated due to values of all patients being 0.

  • BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; DAPSA, Disease Activity index for Psoriatic Arthritis; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; LDI, Leeds Dactylitis Index; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; NAPSI, Nail Psoriasis Severity Index; PASDAS, Psoriatic Arthritis Disease Activity Score; PASI, Psoriasis Area Severity Index; SJC, Swollen Joint Count; TJC, Tender Joint Count; VAS, visual analogue scale.